New York State Cystic Fibrosis Consortium: The First 2.5 Years of Experience With Cystic Fibrosis Newborn Screening in an Ethnically Diverse Population

OBJECTIVE. The purpose of this work was to report on the first 2.5 years of newborn screening for cystic fibrosis in New York. METHODS. Directors of the 11 New York cystic fibrosis centers were asked to provide mutation data, demographic data, and selected laboratory results for each patient diagnosed by newborn screening and followed at their center. Summary data were also submitted from the New York newborn screening laboratory on the total number of patients screened, the number of positive screens, and the number of patients that were lost to follow-up. A second survey was submitted by each center regarding the availability of genetic counseling services at the center. RESULTS. A total of 106 patients with cystic fibrosis were diagnosed through newborn screening in the first 2.5 years and followed at the 11 Cystic Fibrosis Foundation–sponsored cystic fibrosis care centers in New York. Two screen-negative infants were subsequently diagnosed with cystic fibrosis when symptoms developed. The allele frequency of ΔF508 was 57.4%, which is somewhat lower than the allele frequency of ΔF508 in the US cystic fibrosis population of 70%. There were 90 non-Hispanic white (84%), 12 Hispanic, 2 Asian, and 1 black infants diagnosed with cystic fibrosis during this period. Five patients were diagnosed secondary to a positive screen based on a high immunoreactive trypsinogen and no mutations. CONCLUSIONS. Newborn screening for cystic fibrosis has been effectively conducted in New York using a unique screening algorithm that was designed to be inclusive of the diverse racial makeup of the state. However, this algorithm results in a high false-positive rate, and a large number of healthy newborns are referred for confirmatory sweat tests and genetic counseling. This experience indicates that it would be helpful to convene a working group of cystic fibrosis newborn screening specialists to evaluate which mutations should be included in a newborn screening panel.

[1]  J. Gustafson,et al.  Cystic Fibrosis , 2009, Journal of the Iowa Medical Society.

[2]  卢杰,et al.  Cystic fibrosis , 2007 .

[3]  B. Therrell,et al.  Understanding newborn screening system issues with emphasis on cystic fibrosis screening. , 2005, The Journal of pediatrics.

[4]  R. Laessig,et al.  Newborn screening for cystic fibrosis in Wisconsin: nine-year experience with routine trypsinogen/DNA testing. , 2005, The Journal of pediatrics.

[5]  Terry B. White,et al.  Newborn screening for cystic fibrosis: an opportunity to improve care and outcomes. , 2005, The Journal of pediatrics.

[6]  R. Parad,et al.  Diagnostic dilemmas resulting from the immunoreactive trypsinogen/DNA cystic fibrosis newborn screening algorithm. , 2005, The Journal of pediatrics.

[7]  J. Zieleński,et al.  Two-tiered immunoreactive trypsinogen-based newborn screening for cystic fibrosis in Colorado: screening efficacy and diagnostic outcomes. , 2005, The Journal of pediatrics.

[8]  R. Koscik,et al.  Psychosocial Risk Associated With Newborn Screening for Cystic Fibrosis: Parents’ Experience While Awaiting the Sweat-Test Appointment , 2005, Pediatrics.

[9]  B. Wilfond,et al.  Policy issues for expanding newborn screening programs: the cystic fibrosis newborn screening experience in the United States. , 2005, The Journal of pediatrics.

[10]  L. Silverman,et al.  CFTR mutation distribution among U.S. Hispanic and African American individuals: Evaluation in cystic fibrosis patient and carrier screening populations , 2004, Genetics in Medicine.

[11]  Victoria M. Pratt,et al.  Cystic fibrosis population carrier screening: 2004 revision of American College of Medical Genetics mutation panel , 2004, Genetics in Medicine.

[12]  R. Parad,et al.  Population-based newborn screening for genetic disorders when multiple mutation DNA testing is incorporated: a cystic fibrosis newborn screening model demonstrating increased sensitivity but more carrier detections. , 2004, Pediatrics.

[13]  M. Knowles,et al.  The I148T CFTR allele occurs on multiple haplotypes: A complex allele is associated with cystic fibrosis , 2002, Genetics in Medicine.

[14]  P. Lebecque,et al.  Mutations of the cystic fibrosis gene and intermediate sweat chloride levels in children. , 2002, American journal of respiratory and critical care medicine.

[15]  R. Heim,et al.  Improved detection of cystic fibrosis mutations in the heterogeneous U.S. population using an expanded, pan-ethnic mutation panel , 2001, Genetics in medicine : official journal of the American College of Medical Genetics.

[16]  P. Farrell,et al.  Genetic Counseling and Neonatal Screening for Cystic Fibrosis: An Assessment of the Communication Process , 2001, Pediatrics.

[17]  K. Klinger,et al.  Laboratory standards and guidelines for population-based cystic fibrosis carrier screening , 2001, Genetics in Medicine.

[18]  Dodge Ja.  Neonatal screening for cystic fibrosis , 1998 .

[19]  M. Kosorok,et al.  Newborn screening for cystic fibrosis in Wisconsin: comparison of biochemical and molecular methods. , 1997, Pediatrics.

[20]  M. Welsh,et al.  Molecular mechanisms of CFTR chloride channel dysfunction in cystic fibrosis , 1993, Cell.

[21]  L. Brown,et al.  Diagnostic Imaging of the Lung , 1991 .

[22]  R. Laessig,et al.  Newborn screening for cystic fibrosis is complicated by age-related decline in immunoreactive trypsinogen levels. , 1990, Pediatrics.

[23]  C. Mellis,et al.  Diagnostic delay in cystic fibrosis: lessons from newborn screening. , 1983, Archives of disease in childhood.

[24]  A. N. Exton-smith,et al.  USES AND ABUSES OF CHLORMETHIAZOLE , 1979, The Lancet.

[25]  RobertB. Elliott,et al.  CYSTIC-FIBROSIS SCREENING IN THE NEWBORN , 1977, The Lancet.

[26]  M. Giovannini,et al.  [Neonatal screening for cystic fibrosis]. , 1977, Minerva medica.

[27]  M. Kosorok,et al.  Early diagnosis of cystic fibrosis through neonatal screening prevents severe malnutrition and improves long-term growth. Wisconsin Cystic Fibrosis Neonatal Screening Study Group. , 2001, Pediatrics.

[28]  P. Gasparini,et al.  Genetics of cystic fibrosis. , 1991, Digestive diseases.

[29]  R. Laessig,et al.  Immunoreactive trypsinogen screening for cystic fibrosis: Characterization of infants with a false‐positive screening test , 1989, Pediatric pulmonology.